Tuesday, 04 March 2025

 

 

LATEST NEWS Indian Navy's East Coast Motor Car Rally Flags Off from Kolkata to Inspire Youth & Honor Maritime Heritage Droupadi Murmu Inaugurates Visitor’s Conference 2024-25 IAF Capability Enhancement Report Presented to Defence Minister Rajnath Singh National duty of every citizen to contribute to the welfare of soldiers & their families : Rajnath Singh at CSR Conclave Yudh Nashian Virudh: DC urges social, religious, sports organisations to come forward against drug abuse First All India Police Kabaddi Cluster Kicks Off in Jalandhar Randeep Hooda Shares Stunning Wildlife Photos, Advocates Conservation on World Wildlife Day Harjot Singh Bains & Finland Ambassador Launch Teacher Training Program Yudh Nashian Virudh : Big action on illegal property of Drug Smuggler in Bathinda Is Anora Available On OTT? Let’s Explore with 5 Dariya News From Nominees to Winners: The Inside Scoop on the Oscars Academy Awards India and Nepal Sign MoU to Strengthen Cooperation in Water, Sanitation, and Hygiene (WASH) INS Shardul, INS Sujata, and ICGS Veera Arrive in Thailand to Strengthen Maritime Cooperation India and Japan Declare 2025-26 as Year of Science & Technology Exchange Oscar Winning Actress Mikey Madison Net Worth 2025: Unveiling Her Income Sources & Career Highlights Sanjeev Arora Discusses Industrial Concerns with Bhagwant Mann India’s R&D Spending Doubles in a Decade, Driving Innovation in AI, Biotech & Quantum Computing Amit Shah Inaugurates Workshop on Sustainability & Circularity in Dairy Sector Punjab Police Busts Cybercrime Racket: Prime Accused Arrested for Running Fake Mining Department Website Himanshu Jain orders Health Department to promote anti-drug campaign to every village of Distt Rupnagar The LaLiga Showdown: Barcelona Vs Real Madrid

 

Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing

Supriya Lifescience becomes the first Indian company to receive nod for Esketamine Hydrochloride from Brazil’s health authority ANVISA

Health,Dr. Satish Wagh,Supriya Lifescience Ltd, CADIFA, LATAM, Mumbai

Web Admin

Web Admin

5 Dariya News

Mumbai , 09 Dec 2024

Supriya Lifescience Ltd., a global pharmaceutical industry leader, achieved two significant milestones, strengthening its position in international markets. The company has acquired approval from Brazil's health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, which is a major step in growing its product range in Brazil and the rest of LATAM. 

Supriya Lifescience is the first firm in Brazil to have received regulatory permission for this highly specialized pharmaceutical. Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. 

This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. 

This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility.

Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd. stated, "Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil."

With CADIFA approval in place, Supriya Lifescience is now ready to tap into the fast- growing LATAM market. The company's continued focus on innovation, regulatory compliance, and its mission to make high-quality healthcare accessible globally positions it as a key player in the international pharmaceutical landscape.

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. 

Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. 

The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

 

Tags: Health , Dr. Satish Wagh , Supriya Lifescience Ltd , CADIFA , LATAM , Mumbai

 

 

related news

 

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2025 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD